Biological and social determinants of psychosocial sequelae in advanced head and neck cancer survivors receiving immunotherapy
Active Project Grant Awarded Last action
- Award ID
- R01CA281873
- Recipient
-
Emory University UEI S352L5PJLMP8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,981,325
Award facts
- Assistance listing
- 93.393 Cancer Cause and Prevention Research
- Completion date 45% complete
- Place of performance
- Atlanta, GA 30322, USA
Award details come from USAspending.gov.
Description
- Abstract
- The goal of this study is to understand psychosocial sequelae and their biological and social determinants among patients with advanced head and neck cancer (HNC) receiving immunotherapy. Immunotherapy has recently been approved by the FDA for advanced HNC. Patients with advanced cancer often experience substantial clinical prognostic uncertainty, leading to increased psychosocial burden, which, in turn, contributes to worse survival, including in HNC. However, evidence on immunotherapy-related psychosocial burdens is not well-documented, particularly for HNC. Patients with HNC suffer a high psychosocial burden before immunotherapy, likely due to common and long-lasting disease- and treatment-induced side effects (e.g., dry mouth, difficulty opening mouth, and mucositis) that uniquely and significantly impact HNC patients' critical daily functions (e.g., eating and speaking). These psychosocial burdens are speculated to be even higher among those receiving immunotherapy due to advanced cancer stage and uncertainty from immunotherapy length and side effects. Given the scarce evidence, there is a pressing need to investigate psychosocial sequelae (e.g., fatigue, depression) among patients receiving immunotherapy so that specialized care can be targeted to improve QOL and long-term survival. Additionally, identifying biological and social determinants of psychosocial sequelae will highlight risk factors and provide instrumental guidance on interventional strategies. We and others have found that greater inflammation is associated with worse symptomatic side effects, including psychosocial symptoms, and poorer QOL and survival in cancer patients. Nevertheless, whether immunotherapy-associated inflammation is part of the biological determinants of psychosocial sequelae is unknown. Furthermore, an emerging appreciation of the GUT-brain connection has suggested the involvement of the GUT microbiome in psychosocial sequelae. Our preliminary data show that inflammation-related taxa are linked with high psychosocial sequelae, suggesting that restoration of depleted bacteria or their metabolites has the potential to reverse the dysbiosis-associated phenotypes. Still, larger studies are warranted to validate the findings before the development of individual, targeted interventions. Social determinants also impact a wide range of health-related conditions and contribute substantially to health disparities. However, whether and how environmental/community social determinants influence patients' psychosocial sequelae among those receiving immunotherapy is unclear. Therefore, we propose investigating biological and social determinants of psychosocial outcomes for HNC patients receiving immunotherapy. The findings from the study will be instrumental in developing not only individual, personalized, targeted interventions (informed by biological determinants) but also public health and community-level interventions (informed by social determinants), with the ultimate goals of multilevel interventions (combining individual and community levels) to improve psychosocial outcomes and subsequently QOL and long-term survival for those with advanced diseases.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $658,618 | |
| Amendment | $658,403 | |
| Original award | $664,304 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| The Univeristy Of Texas M.d. Anderson Cancer Center | $290,037 | |
| The Univeristy Of Texas M.d. Anderson Cancer Center | $249,042 | |
| The Univeristy Of Texas M.d. Anderson Cancer Center | $240,763 |
Quick answers
Who received award R01CA281873?
R01CA281873 was awarded to Emory University by National Cancer Institute (National Institutes of Health) on August 27, 2024.
How much is award R01CA281873 worth?
$1,981,325 has been obligated on R01CA281873.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award